Table 4.

Phenotype Effect of Raltegravir Resistance Mutations on Raltegravir and Elvitegravir Susceptibility and Replication Capacity

		Fold Changeb
Patient and Time, mo	Mutationsa	Raltegravir	Elvitegravir	Replication Capacityb
Patient 12
0	T97A	1.2 ± 0.1	1.2 ± 0.4	100 ± 9.7
1	T97A, Y143R	28.0 ± 7.3	4.6 ± 0.9	17.3 ± 5.4
3	T97A, Y143R	33.5 ± 7.8	6.6 ± 2.9	13.3 ± 8.8
7	T97A, Y143R, T112A/T	59.4	4.8	>100
9	T97A, Y143R, T112A/T	96.1	7.5	>100
12	T97A, Y143R, T112A, E157E/Q	205.5	14.2	>100
Patient 27
0	No resistance mutations	0.4	0.5	100 ± 2.8
6	G140S, Q148H	313.3	>456.0	8.9 ± 2.4
9	G140S, Q148H	232.4	>456.0	33.5 ± 2.3
12	G140S, Q148H, S119S/T, T125T/A	248.0	>456.0	79.9 ± 7.0
Patient 84
0	No resistance mutations	0.9 ± 0.0	0.7 ± 0.1	100
4	G140S, Q148R	34.4	50.6	ND
5	G140S, Q148Q/R	1.4 ± 0.3	1.1 ± 0.2	>100
Patient 69
0	No resistance mutations	1.3	0.8	100 ± 11.2
4	E92E/A, N155Hc	7.8	27.7	17.4 ± 5.5
5	E92A, N155H	31.6 ± 7.4	117.5 ± 34.4	41.3 ± 19.5
7	V151I, N155H	5.4 ± 1.9	7.5 ± 2.3	24.0 ± 7.8
Patient 81
0	No resistance mutations	0.77	1.0	100 ± 7.5
3	N155H	4.5	29.5	43.4 ± 15.7
Patient 141
0	No resistance mutations	ND	ND	ND
6	V151I, N155H, G163G/R	11.7	32.0	ND
Patient 229
0	No resistance mutations	1.2	0.8	100 ± 8.0
11	Y143C, N155H, S230R	1255.3 ± 297.1	625.3 ± 382.9	62.4 ± 19.3

Fold changes are mean values from 1 or 2 experiments, each performed with 4 replicate determinations in duplicate plates. Replication capacity experiments were performed in triplicate. Bold and underlined type indicates primary raltegravir resistance mutations; bold type, secondary raltegravir resistance mutations.

^aMutations found in recombinant viruses.

^bStandard deviations were determined only when 2 experiments were performed. ND: not determined.

^cMutations found in plasma sample.